Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.34 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.34 |
| ▸ | BCL6 | P41182 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.34 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | STK17B | O94768 | 1/20 | 0.33 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25174188 | 0.99 | EGFR (0.34) | EGFRPTK6BCL6ALDH1A1L3MBTL1 | |
| SCHEMBL24105194 | 0.92 | AURKA (0.33) | ALDH1A1L3MBTL1CYP19A1 | |
| SCHEMBL24105197 | 0.92 | EGFR (0.35) | EGFRPTK6BCL6ALDH1A1L3MBTL1 | |
| SCHEMBL30167900 | 0.92 | EGFR (0.35) | EGFRPTK6BCL6ALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL30168158 | 0.92 | AURKA (0.32) | ALDH1A1L3MBTL1CYP19A1 | |
| SCHEMBL25447130 | 0.89 | BRD4 (0.38) | EGFRPTK6BCL6 | |
| SCHEMBL30167782 | 0.89 | AURKA (0.39) | ALDH1A1CYP19A1 | |
| SCHEMBL24105052 | 0.89 | AURKA (0.39) | ALDH1A1CYP19A1 | |
| SCHEMBL22124604 | 0.85 | PTK6 (0.41) | EGFRPTK6BCL6NCOR2BCDIN3D | |
| SCHEMBL30171566 | 0.85 | PTK6 (0.41) | EGFRPTK6BCL6NCOR2BCDIN3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | claimed |
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2021249893-A1 | NOVEL IMIDAZO-PYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | XDH, MYD88, IKZF3 | EGFR 1449/4885PTK6 2213/4885BCL6 4119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.